19-44708135-T-C
Position:
Variant summary
Our verdict is Benign. Variant got -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BA1
The NM_001039213.4(CEACAM16):āc.1215T>Cā(p.Thr405Thr) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.858 in 1,606,178 control chromosomes in the GnomAD database, including 591,867 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ā ).
Frequency
Genomes: š 0.89 ( 59993 hom., cov: 33)
Exomes š: 0.85 ( 531874 hom. )
Consequence
CEACAM16
NM_001039213.4 synonymous
NM_001039213.4 synonymous
Scores
1
Clinical Significance
Conservation
PhyloP100: -1.92
Genes affected
CEACAM16 (HGNC:31948): (CEA cell adhesion molecule 16, tectorial membrane component) The protein encoded by this gene is a secreted glycoprotein that in mouse interacts with tectorial membrane proteins in the inner ear. The encoded adhesion protein is found in cochlear outer hair cells and appears to be important for proper hearing over an extended frequency range. Defects in this gene likely are a cause of non-syndromic autosomal dominant hearing loss. [provided by RefSeq, May 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -19 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.41).
BP6
Variant 19-44708135-T-C is Benign according to our data. Variant chr19-44708135-T-C is described in ClinVar as [Benign]. Clinvar id is 769228.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-1.92 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.96 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CEACAM16 | NM_001039213.4 | c.1215T>C | p.Thr405Thr | synonymous_variant | 6/7 | ENST00000587331.7 | NP_001034302.2 | |
CEACAM16 | XM_017026795.2 | c.1215T>C | p.Thr405Thr | synonymous_variant | 5/5 | XP_016882284.1 | ||
CEACAM16-AS1 | NR_186815.1 | n.348-8958A>G | intron_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CEACAM16 | ENST00000587331.7 | c.1215T>C | p.Thr405Thr | synonymous_variant | 6/7 | 1 | NM_001039213.4 | ENSP00000466561.1 |
Frequencies
GnomAD3 genomes AF: 0.885 AC: 134654AN: 152154Hom.: 59930 Cov.: 33
GnomAD3 genomes
AF:
AC:
134654
AN:
152154
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.855 AC: 1242633AN: 1453906Hom.: 531874 Cov.: 73 AF XY: 0.855 AC XY: 617749AN XY: 722278
GnomAD4 exome
AF:
AC:
1242633
AN:
1453906
Hom.:
Cov.:
73
AF XY:
AC XY:
617749
AN XY:
722278
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.885 AC: 134775AN: 152272Hom.: 59993 Cov.: 33 AF XY: 0.883 AC XY: 65718AN XY: 74446
GnomAD4 genome
AF:
AC:
134775
AN:
152272
Hom.:
Cov.:
33
AF XY:
AC XY:
65718
AN XY:
74446
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 30, 2023 | The p.Thr405Thr variant in CEACAM16 is classified as benign because it has been identified in 96.8% (40107/41446) of African chromosomes by gnomAD (http://gnomad.broadinstitute.org). Additionally it does not alter an amino acid residue, is not located within the splice consensus site, and computational splice prediction tools do not predict an impact on splicing. ACMG/AMP Criteria applied: BA1, BP4, BP7. - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at